One challenging aspect in the clinical development of molecularly targeted therapies, which
represent a new and promising approach to treating cancers, has been the identification of …

Background BRAF V600 mutations occur in various nonmelanoma cancers. We undertook
a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–…

Background Cetuximab, a chimeric mouse–human IgG1 monoclonal antibody against the
epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell …

Mutationally activated kinases define a clinically validated class of targets for cancer drug
therapy 1 . However, the efficacy of kinase inhibitors in patients whose tumours harbour such …

Purpose Panitumumab is a fully human anti–epidermal growth factor receptor (EGFR)
monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory …

Background Maintaining health of healthcare workers with vaccination is a major component
of pandemic preparedness and acceptance of vaccinations is essential to its success. This …

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …

Background Few effective treatments exist for patients with advanced urothelial carcinoma
that has progressed after platinum-based chemotherapy. We assessed the activity and safety …

Purpose BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal
cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 inhibitor…

Inhibitors of the kinase mammalian target of rapamycin (mTOR) have shown sporadic activity
in cancer trials, leading to confusion about the appropriate clinical setting for their use. …